-
The Role of Mitochondria in Statin-Induced Myopathy Drug Saf. (IF 4.2) Pub Date : 2024-03-16 Gavin Bell, Anastasia Thoma, Iain P. Hargreaves, Adam P. Lightfoot
-
The Problems with Online Health Product Sales: How can Regulations be Improved? Drug Saf. (IF 4.2) Pub Date : 2024-03-14
Abstract With the rapid proliferation of online businesses, national authorities are facing challenges managing the online supply of illegal health products due to the anonymity of the internet, increasing number of global syndicates, new technologies, and inability to enforce against overseas sellers. This paper describes these challenges and the Health Sciences Authority’s regulatory approaches to
-
The Role of Pharmacogenomics in Rare Diseases Drug Saf. (IF 4.2) Pub Date : 2024-03-14 Alice Man, Gabriella S. S. Groeneweg, Colin J. D. Ross, Bruce C. Carleton
Rare diseases have become an increasingly important public health priority due to their collective prevalence and often life-threatening nature. Incentive programs, such as the Orphan Drug Act have been introduced to increase the development of rare disease therapeutics. While the approval of these therapeutics requires supportive data from stringent pre-market studies, these data lack the ability
-
An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014–2022) Following the Introduction of GSK’s Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older Drug Saf. (IF 4.2) Pub Date : 2024-03-14
Abstract Introduction Seasonal influenza is associated with substantial public health burden. The objective of this study was to assess the safety of inactivated quadrivalent seasonal influenza vaccine (IIV4, Fluarix Tetra, GSK, Belgium) in subjects aged ≥ 6 months in Korea. Methods This prospective, observational, non-comparative, multi-centre post-marketing surveillance study was conducted in Korea
-
Drug–Drug Interactions and Actual Harm to Hospitalized Patients: A Multicentre Study Examining the Prevalence Pre- and Post-Electronic Medication System Implementation Drug Saf. (IF 4.2) Pub Date : 2024-03-13 Ling Li, Jannah Baker, Renee Quirk, Danielle Deidun, Maria Moran, Ahmed Abo Salem, Nanda Aryal, Bethany A. Van Dort, Wu Yi Zheng, Andrew Hargreaves, Paula Doherty, Sarah N. Hilmer, Richard O. Day, Johanna I. Westbrook, Melissa T. Baysari
-
The Reporting Recommendations Intended for Pharmaceutical Risk Minimization Evaluation Studies: Standards for Reporting of Implementation Studies Extension (RIMES-SE) Drug Saf. (IF 4.2) Pub Date : 2024-03-13 Meredith Y. Smith, Elaine H. Morrato, Nallely Mora, Viviana Nguyen, Hilary Pinnock, Almut G. Winterstein
-
Drug-Gene Risk Stratification in Patients with Suspected Drug-Induced Interstitial Lung Disease Drug Saf. (IF 4.2) Pub Date : 2024-03-09 Marjolein Drent, Petal A. Wijnen, Naomi T. Jessurun, Ankie M. Harmsze, Otto Bekers, Aalt Bast
-
Using Social Media as a Source of Real-World Data for Pharmaceutical Drug Development and Regulatory Decision Making Drug Saf. (IF 4.2) Pub Date : 2024-03-06
Abstract Introduction While pharmaceutical companies aim to leverage real-world data (RWD) to bridge the gap between clinical drug development and real-world patient outcomes, extant research has mainly focused on the use of social media in a post-approval safety-surveillance setting. Recent regulatory and technological developments indicate that social media may serve as a rich source to expand the
-
Risk of Systemic Inflammatory Response Syndrome Following Preoperative Glucocorticoids Administration in Patients After Percutaneous Nephrolithotomy: A Retrospective Cohort Study Drug Saf. (IF 4.2) Pub Date : 2024-03-05 Jingping Hu, Chaojin Chen, Xiaoyue Li, Xiangyang Zang, Jie Ke, Shaoli Zhou, Haiyan Mai, Chulian Gong
-
Risk Factors Associated with Medication Administration Errors in Children: A Prospective Direct Observational Study of Paediatric Inpatients Drug Saf. (IF 4.2) Pub Date : 2024-03-05 Johanna I. Westbrook, Ling Li, Amanda Woods, Tim Badgery-Parker, Virginia Mumford, Alison Merchant, Erin Fitzpatrick, Magdalena Z. Raban
Introduction Limited evidence exists regarding medication administration errors (MAEs) on general paediatric wards or associated risk factors exists. Objective The aim of this study was to identify nurse, medication, and work-environment factors associated with MAEs among paediatric inpatients. Methods This was a prospective, direct observational study of 298 nurses in a paediatric referral hospital
-
Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS) Drug Saf. (IF 4.2) Pub Date : 2024-02-27 Pedro L. Moro, Carol Ennulat, Hannah Brown, Gina Woody, Bicheng Zhang, Paige Marquez, Emily Jane Woo, John R. Su
Introduction Bivalent mRNA coronavirus disease 2019 (COVID-19) vaccines may be simultaneously administered with other recommended vaccines, including seasonal influenza vaccines. However, few studies have evaluated the safety of co-administration of bivalent mRNA COVID-19 and seasonal influenza vaccines. Objective The aim was to describe reports to the Vaccine Adverse Event Reporting System (VAERS)
-
In Utero Exposure to Antibiotics and Risk of Serious Infections in the First Year of Life Drug Saf. (IF 4.2) Pub Date : 2024-02-26
Abstract Introduction and Objective Given the high prevalence of antibiotic prescription during pregnancy in France and previous studies suggesting an increased risk of infection in offspring with such exposures, our study aimed to investigate the association between prenatal exposure to systemic antibiotics and serious infections in full-term infants during their first year of life. Methods We conducted
-
A Comparison of Signals of Designated Medical Events and Non-designated Medical Events: Results from a Scoping Review Drug Saf. (IF 4.2) Pub Date : 2024-02-24 Daniele Sartori, Jeffrey K. Aronson, Nils Erlanson, G. Niklas Norén, Igho J. Onakpoya
-
The Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines and Future Directions in Enhancing Vaccine Safety Globally Drug Saf. (IF 4.2) Pub Date : 2024-02-23 Irina Caplanusi, Agnieszka Szmigiel, Menno van der Elst, Marie Louise Schougaard Christiansen, Steffen Thirstrup, Cosimo Zaccaria, Bénédicte Cappelli, Georgy Genov, Sabine Straus
-
Detection Algorithms for Simple Two-Group Comparisons Using Spontaneous Reporting Systems Drug Saf. (IF 4.2) Pub Date : 2024-02-22 Yoshihiro Noguchi, Tomoaki Yoshimura
-
Tacrolimus-Induced Neurotoxicity After Transplant: A Literature Review Drug Saf. (IF 4.2) Pub Date : 2024-02-14
Abstract Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used globally to prevent rejection after organ transplantation. Although it significantly improves outcomes for solid organ transplant patients, it is associated with various side effects such as nephrotoxicity and neurotoxicity. Tacrolimus-induced neurotoxicity is frequently encountered in clinical practice and can present with
-
Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy Drug Saf. (IF 4.2) Pub Date : 2024-02-14
Abstract Hepatitis B virus reactivation (HBVr) during and after immunosuppressive/immunomodulatory (IS/IM) therapy is associated with significant morbidity and mortality, including hepatic decompensation and acute liver failure. The risk of HBVr with IS/IM has been heterogeneous and often unpredictable. As a result, patients with active or previous HBV infection are often excluded from clinical drug
-
Sociodemographic Characteristics of Adverse Event Reporting in the USA: An Ecologic Study Drug Saf. (IF 4.2) Pub Date : 2024-02-14 Monica A. Muñoz, Gerald J. Dal Pan, Yu-Jung Jenny Wei, Hong Xiao, Chris Delcher, Andrew Giffin, Nabila Sadiq, Almut G. Winterstein
-
Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis Drug Saf. (IF 4.2) Pub Date : 2024-02-07 Lorenzo Vittorio Rindi, Drieda Zaçe, Neva Braccialarghe, Barbara Massa, Virginia Barchi, Roberta Iannazzo, Ilenia Fato, Francesco De Maria, Dimitra Kontogiannis, Vincenzo Malagnino, Loredana Sarmati, Marco Iannetta
-
Exploring the Role of Guidelines in Contributing to Medication Errors: A Descriptive Analysis of National Patient Safety Incident Data Drug Saf. (IF 4.2) Pub Date : 2024-02-02
Abstract Introduction Clinical guidelines can contribute to medication errors but there is no overall understanding of how and where these occur. Objectives We aimed to identify guideline-related medication errors reported via a national incident reporting system, and describe types of error, stages of medication use, guidelines, drugs, specialties and clinical locations most commonly associated with
-
Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review Drug Saf. (IF 4.2) Pub Date : 2024-01-25
Abstract Background Glucagon-like peptide 1 receptor agonists (GLP1RAs) are used in the treatment of diabetes and obesity. Their slowing effect of gastric emptying might change oral drug absorption, potentially affecting pharmacokinetics, particularly in the case of medications with a narrow therapeutic index. Purpose The purpose of this systematic review is to summarize data on drug-drug interactions
-
Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative Drug Saf. (IF 4.2) Pub Date : 2024-01-13
Abstract The elderly demographic is the fastest-growing segment of the world’s population and is projected to exceed 1.5 billion people by 2050. With multimorbidity, polypharmacy, susceptibility to drug–drug interactions, and frailty as distinct risk factors, elderly patients are especially vulnerable to developing potentially life-threatening safety events such as serious forms of drug-induced liver
-
Validation of a Novel Method to Assess the Clinical Quality of Information in Pregnancy-Related Pharmacovigilance Case Reports: A ConcePTION Project Drug Saf. (IF 4.2) Pub Date : 2024-01-06 Yrea R. J. van Rijt-Weetink, Toine C. G. Egberts, Florence P. A. M. van Hunsel, David J. Lewis, Laura M. Yates, Ursula Winterfeld, Eugène P. van Puijenbroek
-
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS Drug Saf. (IF 4.2) Pub Date : 2024-01-04 Michele Fusaroli, Valentina Giunchi, Vera Battini, Stefano Puligheddu, Charles Khouri, Carla Carnovale, Emanuel Raschi, Elisabetta Poluzzi
-
Risk of Major Bleeding Associated with Concomitant Direct-Acting Oral Anticoagulant and Clopidogrel Use: A Retrospective Cohort Study Drug Saf. (IF 4.2) Pub Date : 2023-12-23
Abstract Background and Aim Combined anticoagulant-antiplatelet therapy is often indicated in adults with cardiovascular disease and atrial fibrillation or venous thromboembolism. The study aim was to assess the comparative risk of bleeding between rivaroxaban and apixaban when combined with clopidogrel. Methods We conducted a retrospective cohort study of commercially insured US adults newly treated
-
International Trends in Adverse Drug Event-Related Mortality from 2001 to 2019: An Analysis of the World Health Organization Mortality Database from 54 Countries Drug Saf. (IF 4.2) Pub Date : 2023-12-22 Toshihiro Koyama, Shunya Iinuma, Michio Yamamoto, Takahiro Niimura, Yuka Osaki, Sayoko Nishimura, Ko Harada, Yoshito Zamami, Hideharu Hagiya
-
Appeal for Increasing the Impact of Pharmacovigilance Drug Saf. (IF 4.2) Pub Date : 2023-12-20 Agnes C. Kant
-
The Critical Intersect of Regulations, Health Technology Assessment, and Drug Safety Assessments Drug Saf. (IF 4.2) Pub Date : 2023-12-19 Wen-Wen Yang, Yi-Chen Juan, Grace Hui-Min Wu, Raoh-Fang Pwu
Health technology assessment (HTA) is a multidisciplinary process that determines the value of health technology at different points in its lifecycle. Safety issues have become more important since regulatory authorities are increasingly adopting flexible standards, processes, and evidentiary requirements for drug approval. In this article, we compared the different role of regulatory authorities and
-
Improving Data Collection in Pregnancy Safety Studies: Towards Standardisation of Data Elements in Pregnancy Reports from Public and Private Partners, A Contribution from the ConcePTION Project Drug Saf. (IF 4.2) Pub Date : 2023-12-19 Guillaume Favre, Jonathan L. Richardson, Alan Moore, Yvonne Geissbühler, Valentine Jehl, Alison Oliver, Svetlana Shechtman, Orna Diav-Citrin, Maya Berlin, Tal De Haan, David Baud, Alice Panchaud, Anil Mor, Meritxell Sabidó, Sabrina de Souza, Christina Chambers, Yrea R. J. van Rijt-Weetink, Eugène P. van Puijenbroek, Laura M. Yates, François Girardin, Michael Stellfeld, Ursula Winterfeld
Introduction and Objective The ConcePTION project aims to improve the way medication use during pregnancy is studied. This includes exploring the possibility of developing a distributed data processing and analysis infrastructure using a common data model that could form a foundational platform for future surveillance and research. A prerequisite would be that data from various data access providers
-
Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study Drug Saf. (IF 4.2) Pub Date : 2023-12-12 Simon Xiwen Qin, Franco Wing Tak Cheng, Wang Chun Kwok, Lydia W. Y. Fung, Tian Tian Ma, Hei Hang Edmund Yiu, Chloe Bloom, Christine F. McDonald, Ching-Lung Cheung, Francisco Tsz Tsun Lai, Celine Sze Ling Chui, Xue Li, Carlos King Ho Wong, Eric Yuk Fai Wan, Ian Chi Kei Wong, Esther Wai Yin Chan
-
Promoting Collaboration of Regulators and Patients in Improving Drug Safety and Regulatory Decision Making Drug Saf. (IF 4.2) Pub Date : 2023-12-11 Yoong Khean Khoo, John C. W. Lim, Wei Chuen Tan-Koi, Nokuthula Sikhethiwe Kitikiti, Ai Ling Sim-Devadas
Pharmacovigilance involves a continuous process of evaluating, monitoring and communicating the safety profile of a medicine throughout its life cycle. This process involves a range of stakeholders, including national regulatory authorities, industry, health organisations, healthcare providers and patients. Although patients are the end users of medicines and experts in their medical conditions, patient
-
SGLT2 Inhibitor Use and Risk of Breast Cancer Among Adult Women with Type 2 Diabetes Drug Saf. (IF 4.2) Pub Date : 2023-12-09 Fengge Wang, Michael Hendryx, Nianjun Liu, Aurelian Bidulescu, Anirban K. Mitra, Juhua Luo
-
Optimizing Signal Management in a Vaccine Adverse Event Reporting System: A Proof-of-Concept with COVID-19 Vaccines Using Signs, Symptoms, and Natural Language Processing Drug Saf. (IF 4.2) Pub Date : 2023-12-07 Guojun Dong, Andrew Bate, François Haguinet, Gabriel Westman, Luise Dürlich, Anders Hviid, Maurizio Sessa
-
The Unseen Hand: AI-Based Prescribing Decision Support Tools and the Evaluation of Drug Safety and Effectiveness Drug Saf. (IF 4.2) Pub Date : 2023-11-29 Harriet Dickinson, Dana Y. Teltsch, Jan Feifel, Philip Hunt, Enriqueta Vallejo-Yagüe, Arti V. Virkud, Katoo M. Muylle, Taichi Ochi, Macarius Donneyong, Joseph Zabinski, Victoria Y. Strauss, Juan M. Hincapie-Castillo
The use of artificial intelligence (AI)-based tools to guide prescribing decisions is full of promise and may enhance patient outcomes. These tools can perform actions such as choosing the ‘safest’ medication, choosing between competing medications, promoting de-prescribing or even predicting non-adherence. These tools can exist in a variety of formats; for example, they may be directly integrated
-
An Overview of Regression Models for Adverse Events Analysis Drug Saf. (IF 4.2) Pub Date : 2023-11-25 Elsa Coz, Mathieu Fauvernier, Delphine Maucort-Boulch
-
Chronic Obstructive Pulmonary Disease Adverse Event Signals Associated with Potential Inhibitors of Glutathione Peroxidase 1: A Sequence Symmetry Analysis Drug Saf. (IF 4.2) Pub Date : 2023-11-23 Jack L. Janetzki, Matthew J. Sykes, Michael B. Ward, Nicole L. Pratt
-
A Descriptive Analysis of Adverse Event Reports from the Quebec Cannabis Registry Drug Saf. (IF 4.2) Pub Date : 2023-11-23 Yasmina Hachem, Yola Moride, Anne-Marie Castilloux, Genaro Castillon, Maja Kalaba, Andrée Néron, Rihab Gamaoun, Marc O. Martel, Pierre Beaulieu, Mark Ware, Antonio Vigano
-
Patient-Reported Reasons for Antihypertensive Medication Change: A Quantitative Study Using Social Media Drug Saf. (IF 4.2) Pub Date : 2023-11-23 Cristina Micale, Su Golder, Karen O’Connor, Davy Weissenbacher, Robert Gross, Sean Hennessy, Graciela Gonzalez-Hernandez
-
Comparative Analysis of Information Provided in German Adverse Drug Reaction Reports Sent by Physicians, Pharmacists and Consumers Drug Saf. (IF 4.2) Pub Date : 2023-11-21 Patrick Christ, Diana Dubrall, Matthias Schmid, Bernhardt Sachs
-
The COVID-19 International Drug Pregnancy Registry (COVID-PR): Protocol Considerations Drug Saf. (IF 4.2) Pub Date : 2023-11-16 Diego F. Wyszynski, Aris T. Papageorghiou, Cheryl Renz, Torri D. Metz, Sonia Hernández-Díaz
-
Cognitive Safety is Largely Ignored in Clinical Drug Trials: A Study of Registered Study Protocols Drug Saf. (IF 4.2) Pub Date : 2023-11-16 Arne Reimers, Hanna Ljung
-
Enhancing Pharmacovigilance in Côte d'Ivoire: Impact of GSK’s Training and Mentoring Pilot Project in the Abidjan Region Drug Saf. (IF 4.2) Pub Date : 2023-11-15 Yolanda Guerra Mendoza, Viviane Jusot, Félix Adou, Martin Ota, Diego Mpia Elenge, Tasim Begum, Nkululeko Mdladla, Olga Menang, Jean Claude Yavo, Mamadou Kamagaté
-
The Moroccan Experience of Implementing a University Curriculum for the Pharmacovigilance of Herbal Medicines (Phytovigilance). Drug Saf. (IF 4.2) Pub Date : 2023-11-15 Souad Skalli
-
Application of an Innovative Data Mining Approach Towards Safe Polypharmacy Practice in Older Adults Drug Saf. (IF 4.2) Pub Date : 2023-11-07 Yi Shi, Chien-Wei Chiang, Kathleen T. Unroe, Ximena Oyarzun-Gonzalez, Anna Sun, Yuedi Yang, Katherine M. Hunold, Jeffrey Caterino, Lang Li, Macarius Donneyong, Pengyue Zhang
-
Validation of a Natural Language Machine Learning Model for Safety Literature Surveillance Drug Saf. (IF 4.2) Pub Date : 2023-11-08 Jiyoon Park, Malek Djelassi, Daniel Chima, Robert Hernandez, Vladimir Poroshin, Ana-Maria Iliescu, Douglas Domalik, Noel Southall
-
Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France Drug Saf. (IF 4.2) Pub Date : 2023-11-05 Sibylle de Germay, Allison Singier, Francesco Salvo, Antoine Pariente
-
Pulmonary Toxicity Associated with Immune Checkpoint Inhibitors-Based Therapy: Current Perspectives and Future Directions Drug Saf. (IF 4.2) Pub Date : 2023-11-07 Baohui Hong, Jiabing Zheng, Rong Chen, Caiyun Zheng, Bin Du, Ruping Ni, Jing Yang
-
Drug Utilisation Patterns of Alternatives to Ranitidine-Containing Medicines in Patients Treated with Ranitidine: A Network Analysis of Data from Six European National Databases Drug Saf. (IF 4.2) Pub Date : 2023-10-31 Johnmary T. Arinze, Maria A. J. de Ridder, Dina Vojinovic, Hanne van Ballegooijen, Emanuil Markov, Talita Duarte-Salles, Peter Rijnbeek, Katia M. C. Verhamme
-
Proceedings of the International Ambulatory Drug Safety Symposium: Munich, Germany, June 2023. Drug Saf. (IF 4.2) Pub Date : 2023-11-02 G Caleb Alexander,Daniel Budnitz,Carmel Hughes,Renke Maas,Alpana Mair,Emily G McDonald,Andreas D Meid,Rupert Payne,Hanna M Seidling,Saad Shakir,Samy Suissa,Cara Tannenbaum,Sebastian Schneeweiss,Tobias Dreischulte
-
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis Drug Saf. (IF 4.2) Pub Date : 2023-10-31 Bruce Strober, Laura C. Coates, Mark G. Lebwohl, Atul Deodhar, Evan Leibowitz, Katelyn Rowland, Alexa P. Kollmeier, Megan Miller, Yanli Wang, Shu Li, Soumya D. Chakravarty, Daphne Chan, May Shawi, Ya-Wen Yang, Diamant Thaҫi, Proton Rahman
-
-
Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch Drug Saf. (IF 4.2) Pub Date : 2023-10-30 Sreedhar Sagi, Pradeep Anjaneya, Sameer Kalsekar, Andrea Kottke, Hillel P. Cohen
Background Biosimilars are additional treatment options that are approved based on robust analytical and clinical comparisons with their reference biologic. At the time of initial approval, the full safety profile of a biosimilar is inferred from the reference biologic. Nonetheless, there are still lingering concerns related to the long-term safety of biosimilars. Therefore, we reviewed the post-approval
-
Intravenous Medication Administration Safety with Smart Infusion Pumps in the Neonatal Intensive Care Unit: An Observational Study Drug Saf. (IF 4.2) Pub Date : 2023-10-27 Kumiko O. Schnock, Sara E. Rostas, Catherine S. Yoon, Stuart Lipsitz, David W. Bates, Patricia C. Dykes
-
The Effect of Sex on the Incidence, Latency, Duration and Perceived Burden of Adverse Events Following Seasonal Influenza Vaccination in the Netherlands Drug Saf. (IF 4.2) Pub Date : 2023-10-26 P. Slingerland, Florence P. A. M. van Hunsel, T. Lieber, L. van Balveren, J. W. Duijster
-
Industry Review of Best Practices for Risk Management of Drug-Induced Liver Injury from Development to Real-World Use Drug Saf. (IF 4.2) Pub Date : 2023-10-24 Loreta Marquez, Ritu Raheja, May Chan-Liston, John Marcinak, Alvin Estilo, Liliam Pineda Salgado, Jason Jiang, Curtis Chang, Paul Beninger
-
The Role of ISoP in the Advancement of Pharmacovigilance in Low-and Middle-Income Countries (LMICs). Drug Saf. (IF 4.2) Pub Date : 2023-10-24 Mohamed A Elhawary,Comfort K Ogar,Mónica Tarapués,Angela Caro,Helen Byomire Ndagije,Ghita Benabdallah,Houda Sefiani,Hadir Rostom
-
Sodium-Glucose Cotransporter 2 Inhibitor-Associated "Ketoacidosis" Versus "Diabetic Ketoacidosis": The Importance of Accurate Terminology. Drug Saf. (IF 4.2) Pub Date : 2023-10-17 Tamara Y Milder,David A Milder,Jerry R Greenfield,Richard O Day
-
Levothyroxine Treatment Among Pregnant Women and Risk of Seizure in Children: A Population-Based Cohort Study Drug Saf. (IF 4.2) Pub Date : 2023-10-16 Grace Mengqin Ge, Kenneth K. C. Man, Edmund C. L. Cheung, Patrick Ip, Wing Cheong Leung, Annie W. C. Kung, Ching-Lung Cheung, Ian C. K. Wong
-
Adverse Drug Reactions to Opioids: A Study in a National Pharmacovigilance Database Drug Saf. (IF 4.2) Pub Date : 2023-10-12 Moa Gustafsson, Cristiano Matos, João Joaquim, Joep Scholl, Florence van Hunsel
-
A Multi-method Exploratory Evaluation of a Service Designed to Improve Medication Safety for Patients with Monitored Dosage Systems Following Hospital Discharge Drug Saf. (IF 4.2) Pub Date : 2023-10-11 Fatema A. Alqenae, Douglas Steinke, Hilary Belither, Peter Robertson, Jennifer Bartlett, Jack Wilkinson, Steven D. Williams, Lawrence Brad, Mark Jeffries, Darren M. Ashcroft, Richard N. Keers